SEC Form 4 · accession 0000899243-17-019539
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tony W Ho
Officer — See Remarks
Period of report
Aug 1, 2017
Accepted (ET)
Aug 2, 2017 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 1, 2017 | A | 75,000 | A | — | — | Common Shares | 75,000 | 75,000 | D |
| Stock Options (Right to Buy)F3 | $16.90 | Aug 1, 2017 | A | 260,000 | A | — | Aug 1, 2027 | Common Shares | 260,000 | 260,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- F2The restricted stock units vest in two equal annual installments on 8/1/2018 and 8/1/2019.
- F3This option was granted on August 1, 2017 with respect to 260,000 Common Shares of which 25% shall vest on 8/1/2018 and the remaining 75% shall vest in 36 equal monthly installments on the final day of each succeeding calendar month.
Remarks
Executive Vice President, Head of Research & Development